OnderLaw Lauds Revolutionary Drug Combination that Offers Hope for Women with Ovarian Cancer

Drug Combination Shows Special Promise to Those Diagnosed with Johnson & Johnson Talc-Related Ovarian Cancer

ST. LOUIS, MO, June 23, 2023 /24-7PressRelease/ -- OnderLaw, LLC, a leading legal team representing thousands of women diagnosed with Johnson & Johnson talc-related ovarian cancer, stands alongside women fighting ovarian cancer by sharing news of a groundbreaking treatment. Recent clinical trial data, presented at a major cancer conference, reveals a revolutionary drug combination that demonstrates significant potential in shrinking ovarian cancer tumors, surpassing existing treatment options.

The clinical trials, led by the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, focused on the drug avutometinib in combination with defactinib. In an impressive finding, nearly half of the patients (45%) who received the drug combination experienced significant tumor shrinkage, outperforming other available treatments. Particularly, the treatment showcased an even higher response rate (60%) among patients with a specific mutation known as KRAS-driven ovarian tumors.

This breakthrough offers renewed hope for women diagnosed with low-grade serous ovarian cancer, a subtype that predominantly affects younger women. The results are considered a significant advancement, providing a more effective treatment option compared to existing choices.

Although specific survival data from the trial is pending, previous studies indicate that patients treated with this drug combination live an average of 23 months before cancer progression, representing a substantial improvement over current treatments.

These groundbreaking clinical trial results highlight the potential of the revolutionary drug combination in significantly shrinking tumors and providing a more effective treatment option for women with low-grade serous ovarian cancer. While further research and survival data are necessary, this finding represents a significant breakthrough in the battle against ovarian cancer. Furthermore, it brings hope to women diagnosed with other types of ovarian cancer.

OnderLaw stands ready to support women affected by ovarian cancer. If you suspect you or a loved one has been diagnosed with ovarian cancer after using Johnson's Baby Powder or Shower to Shower for at least one year, contact us for a free, no-obligation consultation.

About OnderLaw, LLC

​​At OnderLaw, LLC, we care about our clients and believe it is our job to provide more than legal experience. Our team provides serious resources to tackle important cases. We have built a strong reputation by successfully handling the most challenging of cases across the country. Be it a claim involving catastrophic injury or death, pharmaceutical or medical device litigation, asbestos, construction accidents, or helping an injured worker, we have a history of success, having delivered over $3.5 billion in settlements and verdicts.

---
Press release service and press release distribution provided by https://www.24-7pressrelease.com
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.